Scarica l'app Stockscreener
0.3991
1.51%
-0.0061
Dopo l'orario di chiusura:
.41
0.0109
+2.73%
Reviva Pharmaceuticals Holdings Inc Borsa (RVPH) Ultime notizie
Is Reviva Pharmaceuticals Holdings Inc. a good long term investmentRapid profit acceleration - Autocar Professional
What drives Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock priceOutstanding risk-reward balance - Autocar Professional
What analysts say about Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock - Autocar Professional
Is Reviva Pharmaceuticals Holdings Inc. Equity Warrant a good long term investmentMassive stock growth - jammulinksnews.com
What analysts say about Reviva Pharmaceuticals Holdings Inc. stockRapid market gains - jammulinksnews.com
Reviva Pharmaceuticals Holdings Inc. Stock Analysis and ForecastStrongest growth potential - Autocar Professional
What drives Reviva Pharmaceuticals Holdings Inc. stock priceUnmatched profit potential - jammulinksnews.com
Can Reviva Pharmaceuticals Holdings Inc. stock recover from recent declineControlled Risk High Reward Plan - Newser
Reviva Pharmaceuticals Holdings Inc. Equity Warrant Stock Analysis and ForecastLightning-fast capital gains - jammulinksnews.com
How Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock performs during market volatilityWealth Building Stock Portfolio - Newser
Why Reviva Pharmaceuticals Holdings Inc. stock attracts strong analyst attentionFree Consultation - Newser
What makes Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock price move sharplyFree Stock Market Entry & Exit Signals - Newser
What makes Reviva Pharmaceuticals Holdings Inc. stock price move sharplyCapital Doubling Tips - Newser
Reviva Pharmaceuticals Holdings Inc: Analyzing RVPH Stock Trends - investchronicle.com
Why Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock attracts strong analyst attentionSmall Risk Large Return Trades - Newser
How Reviva Pharmaceuticals Holdings Inc. stock performs during market volatilityReal Time Stock Signal - Newser
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Reviva Pharmaceuticals’ (RVPH) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Reviva Pharmaceuticals Makes A $10 Million Stock Offering Move - Finimize
Reviva Pharmaceuticals (RVPH) Maintains Buy Rating and Price Tar - GuruFocus
Reviva Pharmaceuticals (RVPH) Launches $10M Public Offering - GuruFocus
Dow Surges 200 Points; US GDP Contracts 0.5% - Benzinga
Reviva Pharmaceuticals (RVPH) Announces Public Offering of Commo - GuruFocus
Reviva Pharmaceuticals (RVPH) Declines After Announcing Public Offering - GuruFocus
Reviva Pharmaceuticals announces public offering of common stock By Investing.com - Investing.com Nigeria
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Rating of “Buy” by Brokerages - Defense World
Ameriprise Financial Inc. Takes $84,000 Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
RVPH: Open Label Extension Results & Key Opinion Leader Discussion - MSN
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewswire
Late-Stage CNS Drug Developer Reviva Pharma Reveals New Pipeline Updates at Major Neuroscience Conference - Stock Titan
Data Readout Positive from Trial of New Schizophrenia Drug - streetwisereports.com
Reviva Pharmaceuticals (NASDAQ:RVPH) Receives Buy Rating from D. Boral Capital - Defense World
Reviva Pharmaceuticals (RVPH) Receives Buy Rating from D. Boral - GuruFocus
Reviva reports positive year-long schizophrenia drug study By Investing.com - Investing.com South Africa
Reviva Pharmaceuticals Holdings, Inc. Announces Positive Full Dataset for 1-Year Phase 3 Recover Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - MarketScreener
Reviva Reports Positive Full Dataset For Phase 3 RECOVER OLE Study Of Brilaroxazine In Schizophrenia - Nasdaq
Reviva reports positive year-long schizophrenia drug study - Investing.com Australia
Reviva Pharmaceuticals (RVPH) Unveils Promising Phase 3 Brilaroxazine Study Results | RVPH Stock News - GuruFocus
0.59%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):